MASI Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.
Company profile
Ticker
MASI
Exchange
Website
CEO
Joseph Kiani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Natus Medical • LivaNova • Outset Medical • Fonar • Cutera • Inmode • Stereotaxis ...
SEC CIK
Corporate docs
IRS number
330368882
MASI stock data
()
News
Masimo Announces FDA Clearance Of Radius PCG For Root Patient Monitoring And Connectivity Platform
12 Apr 21
Masimo Announced New Study Evaluates the Ability of EMMA Capnography to Assess the Respiratory Status of Children With Tracheostomy
15 Mar 21
Recap: Masimo Q4 Earnings
23 Feb 21
Masimo Q4 Adj. EPS $0.98 Beats $0.86 Estimate, Sales $295.10M Beat $287.45M Estimate
23 Feb 21
Masimo Announces U.S. Release Of SoftFlow High-Flow Nasal Cannula Therapy
23 Feb 21
Press releases
Masimo to Present in 20th Annual Needham Healthcare Conference
6 Apr 21
Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using Masimo O3®
6 Apr 21
Study Investigates the Impact of Automating Respiration Rate Measurement Using Masimo Rad-G™ with RRp®
29 Mar 21
Sri Lankan Study Expands Evidence Demonstrating the Benefits of Critical Congenital Heart Disease (CCHD) Screening Using Masimo SET® Pulse Oximetry
22 Mar 21
New Study Evaluates the Ability of Masimo EMMA® Capnography to Assess the Respiratory Status of Children With Tracheostomy
15 Mar 21
Calendar
23 Feb 21
13 Apr 21
2 Jan 22
Financial summary
Quarter (USD) |
Jan 21 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Jan 21 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Masimo earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 645M | 645M | 645M | 645M | 645M | 645M |
Cash burn (monthly) | 9.15M | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | 30.82M | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 614.18M | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 67.2 | n/a | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 21 | Young Micah W | Common Stock | Sell | Dispose S | No | Yes | 239 | 2,087 | 498.79K | 14,593 |
8 Apr 21 | Young Micah W | Common Stock | Option exercise | Aquire M | No | No | 86.95 | 2,087 | 181.46K | 16,680 |
8 Apr 21 | Young Micah W | NQSO Common Stock | Option exercise | Dispose M | No | No | 86.95 | 2,087 | 181.46K | 4,175 |
26 Feb 21 | Young Micah W | NQSO Common Stock | Grant | Aquire A | No | No | 250.73 | 3,956 | 991.89K | 3,956 |
26 Feb 21 | Sampath Anand | NQSO Common Stock | Grant | Aquire A | No | No | 250.73 | 2,637 | 661.18K | 2,637 |
26 Feb 21 | John Todd Koning | NQSO Common Stock | Grant | Aquire A | No | No | 250.73 | 1,483 | 371.83K | 1,483 |
26 Feb 21 | Muhsin Bilal | NQSO Common Stock | Grant | Aquire A | No | No | 250.73 | 7,912 | 1.98M | 7,912 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
82.4% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 475 |
Opened positions | 71 |
Closed positions | 49 |
Increased positions | 177 |
Reduced positions | 144 |
13F shares |
Current |
---|---|
Total value | 12.22B |
Total shares | 45.53M |
Total puts | 54.9K |
Total calls | 135.5K |
Total put/call ratio | 0.4 |
Largest owners |
Shares | Value |
---|---|---|
BLK Blackrock | 8.32M | $2.23B |
Vanguard | 4.6M | $1.23B |
FMR | 3.83M | $1.03B |
Ownership Capital B.V. | 1.73M | $465.37M |
STT State Street | 1.67M | $447.4M |
IVZ Invesco | 1.49M | $400.8M |
Massachusetts Financial Services | 1M | $269.12M |
BK Bank Of New York Mellon | 847.21K | $227.37M |
Champlain Investment Partners | 837.3K | $224.72M |
CS Credit Suisse | 769.88K | $206.62M |
Financial report summary
?Risks
- Summary of Material Risk Factors
- Risks Related to Our Revenues
- Some of our products are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.
- We face competition from other companies, many of which have substantially greater resources than we do. If we do not successfully develop and commercialize enhanced or new products that remain competitive with products or alternative technologies developed by others, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired, adversely affecting our financial condition and results of operations.
- We depend on our domestic and international OEM partners for a portion of our revenue. If they do not devote sufficient resources to the promotion of products that use our technologies, our business would be harmed.
- If we fail to maintain or develop relationships with GPOs, sales of our products would decline.
- Inadequate levels of coverage or reimbursement from governmental or other third-party payers for our products, or for procedures using our products, may cause our revenue to decline or prevent us from realizing revenues from future products.
- Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of existing market participants from certain markets, which could have an adverse effect on our business, results of operations or financial condition.
- Our customers may reduce, delay or cancel purchases due to a variety of factors, such as lower hospital census levels or third-party guidelines, which could adversely affect our business, financial condition and results of operations.
- The loss of any large customer or distributor, or any cancellation or delay of a significant purchase by a large customer, could reduce our net sales and harm our operating results.
- Counterfeit Masimo sensors and third-party medical device reprocessors that reprocess our single-patient-use sensors may harm our reputation. Also, these counterfeit and third-party reprocessed sensors, as well as genuine Masimo reprocessed sensors, are sold at lower prices than new Masimo sensors and could cause our revenue to decline, which may adversely affect our business, financial condition and results of operations.
- Risks Related to Our Intellectual Property
- If the patents we own or license, or our other intellectual property rights, do not adequately protect our technologies, we may lose market share to our competitors and be unable to operate our business profitably.
- If third parties claim that we infringe their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling certain products.
- We believe competitors may currently be violating and may in the future violate our intellectual property rights. As a result, we may initiate litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert management’s attention from implementing our business strategy.
- Risks Related to Our Regulatory Environment
- Our failure to obtain and maintain FDA clearances or approvals on a timely basis, or at all, would prevent us from commercializing our current, upgraded or new products in the U.S., which could severely harm our business.
- The failure of our OEM partners to obtain required FDA clearances or approvals for products that incorporate our technologies could have a negative impact on our revenue.
- If we or our suppliers fail to comply with ongoing regulatory requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.
- Failure to obtain regulatory authorizations in foreign jurisdictions may prevent us from marketing our products abroad.
- Modifications to our marketed devices may require new regulatory clearances or premarket approvals, or may require us to cease marketing or to recall the modified devices until clearances or approvals are obtained.
- Regulatory reforms may impact our ability to develop and commercialize our products and technologies.
- If our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury, we will be subject to medical device reporting regulations, and may need to initiate voluntary corrective actions such as the recall of our products.
- Promotion of our products using claims that are off-label, unsubstantiated, false or misleading could subject us to substantial penalties.
- The regulatory environment governing information, cybersecurity and privacy laws is increasingly demanding and continues to evolve.
- We may be subject to or otherwise affected by federal and state healthcare laws, including fraud and abuse laws, and could face substantial penalties if we are unable to fully comply with these laws.
- Legislative and regulatory changes in the healthcare industry could have a negative impact on our financial performance. Furthermore, our business, financial condition, results of operations and cash flows could be significantly and adversely affected by healthcare reform legislation in the U.S. or in our key international markets.
- Risks Related to Our Business and Operations
- Our business, financial condition and results of operations may be adversely affected by the COVID-19 pandemic.
- If our essential employees who are unable to telework become ill or otherwise incapacitated, our operations may be adversely impacted.
- We may experience conflicts of interest with Cercacor with respect to business opportunities and other matters.
- Rights provided to Cercacor in the Cross-Licensing Agreement may impede a change in control of our company.
- Future strategic initiatives, including acquisitions of businesses and strategic investments, could negatively affect our business, financial condition and results of operations if we fail to integrate the acquired businesses successfully into our existing operations or achieve the desired results of our investment.
- Our credit agreement contains certain covenants and restrictions that may limit our flexibility in operating our business.
- Risks Related to Our Stock
- Concentration of ownership of our stock among our existing directors, executive officers and principal stockholders may prevent new investors from influencing significant corporate decisions.
- Our corporate documents and Delaware law contain provisions that could discourage, delay or prevent a change in control of our company, prevent attempts to replace or remove current management and reduce the market price of our stock.
- Our bylaws provide that the state or federal courts located within the State of Delaware are the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- The laws of foreign countries may not adequately protect our intellectual property rights.
- We may experience significant fluctuations in our periodic financial results and may not maintain our current levels of profitability in the future.
- Future changes in accounting pronouncements and tax laws, or the interpretation thereof, could have a significant impact on our reported results, and may affect our historical reporting of previous transactions.
- If we lose the services of our key personnel, or if we are unable to attract and retain other key personnel, we may not be able to manage our operations or meet our growth objectives.
- We are involved, and may become involved in the future, in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations.
- Changes to government immigration regulations may materially affect our workforce and limit our supply of qualified professionals, or increase our cost of securing workers.
- The risks inherent in operating internationally, including the purchase, sale and shipment of our components and products across international borders, may adversely impact our business, financial condition and results of operations.
- Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates.
- We currently manufacture our products at a limited number of locations and any disruption to, expansion of, or changes in trade programs related to such manufacturing operations could adversely affect our business, financial condition and results of operations.
- If we do not accurately forecast customer demand, we may hold suboptimal inventory levels that could adversely affect our business, financial condition and results of operations.
- If we fail to comply with the reporting obligations of the Securities Exchange Act of 1934, as amended, or if we fail to maintain adequate internal control over financial reporting, our business, results of operations and financial condition and investors’ confidence in us could be adversely affected.
- Changing laws and increasingly complex corporate governance and public disclosure requirements could have an adverse effect on our business and operating results.
- If product liability claims are brought against us, we could face substantial liability and costs.
- We may incur environmental and personal injury liabilities related to certain hazardous materials used in our operations.
- We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
- Discontinuation, reform or replacement of LIBOR and other benchmark rates, or uncertainty related to the potential for any of the foregoing, may adversely affect our business.
- Our stock price may be volatile, and your investment in our stock could suffer a decline in value.
- Our investors could experience substantial dilution of their investments as a result of subsequent exercises of our outstanding options, vesting of outstanding restricted stock units (RSUs) and performance stock units (PSUs), or the grant of future equity awards by us.
- Future resales of our stock, including those by our insiders and a few investment funds, may cause our stock price to decline.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
acquiree, addiction, afterload, air, amazing, andAlternate, audiovisual, AX, Blueprint, Bridge, bridging, Britain, carryover, Centroid, closure, constant, deoxyhemoglobin, disallowance, disinfection, distancing, door, England, epidemic, exciting, extraordinary, factory, fall, familiarize, faster, female, fever, film, fueled, gathering, globe, halting, heard, hemodynamic, humidified, hypercapnic, hypoxemic, incapacitated, infection, Inline, Inter, interbank, inventorship, Ireland, iXBRL, koning, Labour, leader, LiDCO, Lira, LMMV, loved, male, mandatorily, mandatory, media, mediation, MHLW, Minded, Ministry, modular, naltrexone, nerve, Neuchatel, neuromodulation, newly, nondeductible, nonessential, older, oral, organizational, orientation, Overnight, oxyhemoglobin, pace, pandemic, percutaneously, pertinent, pneumatic, posture, precautionary, preload, prescription, probe, prolonged, prompt, quarantine, quiet, reciprocated, redeemable, relaxation, reopening, reorganization, resistance, retract, risky, Safer, sanitation, science, Scotland, situation, sleep, SOFR, softFlow, somatic, stability, stable, stake, stimulator, stockpiling, stroke, struggle, student, succeed, summarized, surfaced, surge, survey, talent, tapering, TCJA, telework, tenure, thermometer, thermometry, thin, threat, TNI, todd, tool, Turkish, UKCA, unredacted, VSM, wake, Watch, women, workplace, Wuhan
Removed:
addressed, age, aim, analyzed, appealed, barker, build, carrier, clarification, compute, conducting, contemplated, Danderyd, david, Discovery, disfavor, drafting, ecosystem, education, eliminate, encouraged, excise, exempted, INDEPENDENCE, insignificant, mail, MINE, print, ramshorst, ratified, repatriation, role, SAB, steven, Sudan, supporting, Sweden, Syria, telephone, terrorism, unite, UNRESOLVED, van
Financial reports
10-K
2020 FY
Annual report
23 Feb 21
10-Q
2020 Q3
Quarterly report
27 Oct 20
10-Q
2020 Q2
Quarterly report
28 Jul 20
10-Q
2020 Q1
Quarterly report
28 Apr 20
10-K
2019 FY
Annual report
19 Feb 20
10-Q
2019 Q3
Quarterly report
30 Oct 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
6 May 19
10-K
2018 FY
Annual report
25 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
Current reports
8-K
Departure of Directors or Certain Officers
7 Apr 21
8-K
Departure of Directors or Certain Officers
26 Feb 21
8-K
Masimo Reports Fourth Quarter and Full-Year 2020 Financial Results
23 Feb 21
8-K
Masimo Expands Suite of Advanced Measurements Through Acquisition of UK-Based LiDCO Group Plc
2 Feb 21
8-K
Masimo Announces Select Preliminary Full-Year 2020 Financial Results and 2021 Guidance
13 Jan 21
8-K
Other Events
2 Nov 20
8-K
Departure of Directors or Certain Officers
29 Oct 20
8-K
Masimo Reports Third Quarter 2020 Financial Results
27 Oct 20
8-K
Masimo Announces Select Preliminary Third Quarter 2020 Financial Results and Updated Full-Year 2020 Guidance
6 Oct 20
8-K
Masimo Reports Second Quarter 2020 Financial Results
28 Jul 20
Registration and prospectus
S-8
Registration of securities for employees
28 Jul 20
S-8
Registration of securities for employees
30 Oct 19
S-3ASR
Automatic shelf registration
26 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 17
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 17
S-8
Registration of securities for employees
9 Jul 17
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 17
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 17
S-8
Registration of securities for employees
14 Feb 17
15-12G
Securities registration termination
28 Feb 16
Proxies
DEFA14A
Additional proxy soliciting materials
20 May 20
DEFA14A
Additional proxy soliciting materials
15 Apr 20
DEF 14A
Definitive proxy
15 Apr 20
DEFA14A
Additional proxy soliciting materials
12 Apr 19
DEF 14A
Definitive proxy
12 Apr 19
DEF 14A
Definitive proxy
19 Apr 18
DEFA14A
Additional proxy soliciting materials
25 May 17
DEFA14A
Additional proxy soliciting materials
23 May 17
DEF 14A
Definitive proxy
11 Apr 17
DEF 14A
Definitive proxy
15 Mar 16
Other
SD
Conflict minerals disclosure
22 May 20
CT ORDER
Confidential treatment order
1 Oct 19
CT ORDER
Confidential treatment order
3 Jul 19
SD
Conflict minerals disclosure
29 May 19
CT ORDER
Confidential treatment order
9 Oct 18
CT ORDER
Confidential treatment order
31 Jul 18
SD
Conflict minerals disclosure
31 May 18
CT ORDER
Confidential treatment order
9 Jul 17
UPLOAD
Letter from SEC
9 Jul 17
CORRESP
Correspondence with SEC
28 Jun 17
Ownership
4
MASIMO / Micah W Young ownership change
12 Apr 21
4
MASIMO / JOE E KIANI ownership change
2 Mar 21
4
MASIMO / Tao Levy ownership change
2 Mar 21
4
MASIMO / Thomas Samuel McClenahan ownership change
2 Mar 21
4
MASIMO / Jon Coleman ownership change
2 Mar 21
4
MASIMO / Yongsam Lee ownership change
2 Mar 21
4
MASIMO / Bilal Muhsin ownership change
2 Mar 21
4
MASIMO / John Todd Koning ownership change
2 Mar 21
4
MASIMO / Anand Sampath ownership change
2 Mar 21
4
MASIMO / Micah W Young ownership change
2 Mar 21
Patents
GRANT
Utility
Low power pulse oximeter
30 Mar 21
A pulse oximeter may reduce power consumption in the absence of overriding conditions.
APP
Utility
Avatar-incentive Healthcare Therapy
25 Mar 21
An avatar-incentive healthcare therapy system has a physiological monitor for generating a physiological parameter indicative of physical health.
GRANT
Utility
Modulated physiological sensor
23 Mar 21
A modulated physiological sensor is a noninvasive device responsive to a physiological reaction of a living being to an internal or external perturbation that propagates to a skin surface area.
GRANT
Utility
Gas sampling line
23 Mar 21
A gas sampling line having a channel for conducting respiratory gases from a patient respiratory interface to a gas monitor, the gas sampling line comprising, i.a., a gas sampling tube comprised of a polyether block amide material, the polyether segments of which comprise polyethyleneoxide.
GRANT
Utility
Hemoglobin display and patient treatment
23 Mar 21
The present disclosure describes embodiments of a patient monitoring system and methods that include the measure and display of hemoglobin statistics.
Transcripts
2020 Q4
Earnings call transcript
24 Feb 21
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
28 Apr 20
2019 Q4
Earnings call transcript
19 Feb 20
2019 Q3
Earnings call transcript
30 Oct 19
2019 Q2
Earnings call transcript
31 Jul 19
2019 Q1
Earnings call transcript
6 May 19
2018 Q4
Earnings call transcript
26 Feb 19
2018 Q3
Earnings call transcript
31 Oct 18
Reddit threads
Healthcare Growth stocks
3 Apr 21
Lemonade Diligence Post - DON'T Buy the Dip
4 Mar 21
Daily General Discussion and spitballin thread
24 Feb 21
Daily Discussion Thread - February 23rd, 2021
23 Feb 21
Daily Discussion Thread - February 22nd, 2021
22 Feb 21
Stupid question. but with companies such as Apple, that are just so big... how is there room to get even bigger?
27 Jan 21